Spero Therapeutics Inc (NASDAQ:SPRO) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 1,270,000 shares, a growth of 18.7% from the August 15th total of 1,070,000 shares. Based on an average daily trading volume, of 240,900 shares, the short-interest ratio is presently 5.3 days. Currently, 8.5% of the shares of the company are short sold.

Shares of NASDAQ:SPRO traded up $0.06 during midday trading on Wednesday, hitting $10.05. The stock had a trading volume of 13,193 shares, compared to its average volume of 189,082. The company’s 50-day moving average price is $11.66 and its 200-day moving average price is $10.96. The company has a market capitalization of $211.32 million, a P/E ratio of -2.30 and a beta of 1.69. Spero Therapeutics has a fifty-two week low of $5.25 and a fifty-two week high of $14.48. The company has a quick ratio of 4.49, a current ratio of 4.49 and a debt-to-equity ratio of 0.06.

Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.17) by $0.32. The business had revenue of $1.73 million during the quarter, compared to analysts’ expectations of $2.95 million. Spero Therapeutics had a negative net margin of 715.20% and a negative return on equity of 103.39%. Research analysts expect that Spero Therapeutics will post -3.67 EPS for the current fiscal year.

A number of research firms have issued reports on SPRO. ValuEngine raised shares of Spero Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, September 11th. HC Wainwright reissued a “buy” rating and issued a $28.00 price objective on shares of Spero Therapeutics in a report on Tuesday, June 2nd. Zacks Investment Research downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 28th. Oppenheimer reissued a “buy” rating and issued a $20.00 price objective on shares of Spero Therapeutics in a report on Tuesday, September 8th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $25.00 price objective (up previously from $21.00) on shares of Spero Therapeutics in a report on Tuesday, September 8th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $21.75.

In related news, CEO Ankit Mahadevia sold 2,293 shares of Spero Therapeutics stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $14.31, for a total transaction of $32,812.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 3,821 shares of company stock valued at $54,587 in the last ninety days. 18.34% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in SPRO. VR Adviser LLC acquired a new position in Spero Therapeutics during the 1st quarter worth approximately $3,830,000. BlackRock Inc. boosted its stake in shares of Spero Therapeutics by 16.7% in the 1st quarter. BlackRock Inc. now owns 881,231 shares of the company’s stock valued at $7,120,000 after purchasing an additional 125,966 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in shares of Spero Therapeutics by 158.1% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 186,350 shares of the company’s stock valued at $2,521,000 after purchasing an additional 114,155 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Spero Therapeutics by 768.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 93,328 shares of the company’s stock valued at $1,260,000 after purchasing an additional 82,587 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its stake in shares of Spero Therapeutics by 15.2% in the 1st quarter. Rock Springs Capital Management LP now owns 605,000 shares of the company’s stock valued at $4,888,000 after purchasing an additional 80,000 shares during the last quarter. Institutional investors and hedge funds own 50.40% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease.

Featured Article: S&P 500 Index

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.